open access

Vol 9, No 1 (2012)
Review paper
Published online: 2012-05-28
Get Citation

Agomelatine — a novel antidepressive drug

Jerzy Landowski
Psychiatria 2012;9(1):11-20.

open access

Vol 9, No 1 (2012)
Prace poglądowe - nadesłane
Published online: 2012-05-28

Abstract

Agomelatine is a novel antidepressant with an unique pharmacological profile characterized by agonism at the melatonergic MT1/MT2 receptors and antagonism at the 5-HT2C receptors. Specific clinical properties correspond to this pharmacological profile as was shown in several clinical trials. Agomelatine is an effective antidepressant with relatively early onset of action, good safety and tolerability. Its antidepressant efficacy is maintained over the long term. Among all antidepressants agomelatine is distinguished by characteristic clinical effect: improvement of sleep and alleviation of anxiety without sedation, weight gain, sexual disturbances and blunted affect. This review of current clinical trials describes the characteristics of agomelatine focusing on its specific efficacy and tolerability in the treatment of depressive episodes. The promising results need further confirmation in clinical trials and everyday practice.

Abstract

Agomelatine is a novel antidepressant with an unique pharmacological profile characterized by agonism at the melatonergic MT1/MT2 receptors and antagonism at the 5-HT2C receptors. Specific clinical properties correspond to this pharmacological profile as was shown in several clinical trials. Agomelatine is an effective antidepressant with relatively early onset of action, good safety and tolerability. Its antidepressant efficacy is maintained over the long term. Among all antidepressants agomelatine is distinguished by characteristic clinical effect: improvement of sleep and alleviation of anxiety without sedation, weight gain, sexual disturbances and blunted affect. This review of current clinical trials describes the characteristics of agomelatine focusing on its specific efficacy and tolerability in the treatment of depressive episodes. The promising results need further confirmation in clinical trials and everyday practice.
Get Citation

Keywords

agomelatine; depressive episode; review

About this article
Title

Agomelatine — a novel antidepressive drug

Journal

Psychiatria (Psychiatry)

Issue

Vol 9, No 1 (2012)

Article type

Review paper

Pages

11-20

Published online

2012-05-28

Bibliographic record

Psychiatria 2012;9(1):11-20.

Keywords

agomelatine
depressive episode
review

Authors

Jerzy Landowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl